VEGFA and neoplasm: The theoretical foundation for utilizing ICIs and anti-VEGF antibodies in HCC treatment rests upon three key concepts: the “cancer-immunity cycle” theory (67, 68), “normalization cancer immunotherapy” (69), and “normalizing tumor vasculature” (70), which is alternatively referred to as “normalization of the tumor microenvironment (TME)” (71).